Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Meeting to be held on November 15 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving ...

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...